Summary
It is well established that neuroleptic drugs are antagonists of brain dopamine receptors. The role of the reported increase in dopamine receptors (measured as 3H-spiperone binding sites) in post-mortem brain tissue from patients with schizophrenia in the aetiology of the disease is, however, unclear. We have found this increase only in chronically neuroleptic-treated patients, indicating that the increase is probably due to this neuroleptic treatment.
Many neuroleptic drugs have a high affinity for a subgroup of 5-hydroxytryptamine receptors, which have also been implicated in schizophrenia. Using the specific ligand 3H-ketanserin, we find that certain neuroleptics have a higher affinity for these 5-HT2 receptors than for the dopamine D2 site. Although changes in these receptors have been reported in schizophrenic brain tissue we have been unable to find any difference in receptor density in cortical tissue from schizophrenics and control subjects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bennett, J. P., Enna, S.J., Bylund, D. B., Gillin, J. C., Wyatt, R.J., Snyder, S. H.: Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psych. 36, 927–934 (1979).
Clow, A., Theodorou, A., Jenner, P., Marsden, C.D.: Changes in rat striatal dopamine turnover and receptor activity during one year’s neuroleptic administration. Eur. J. Pharmac. 63, 135–144 (1980).
Leysen, J. E., Niemegeers, C.J. E., Van Nueten, J. M., Laduron, P. M.: 3H-Ketanserin (R41468), a selective 3H-ligand for serotonin (S2) receptor binding sites. Binding properties, brain distribution and functional role. Mol. Pharmac. 21, 301–304 (1982).
Mackay, A. VP., Bird, E. D., Spokes, E. G., Rossor, M. N., Iversen, L. L., Creese, I., Snyder, S. H.: Dopamine receptors and schizophrenia: drug effect of illness? Lancet ii, 915–916 (1980).
Mackay, A. V. P., Iversen, L. L., Rossor, M., Spokes, E., Bird, E., Arregui, A., Creese, I., Snyder, S. H.: Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psych. 31, 991–997 (1982).
Owen, F., Crow, T.J., Poulter, M., Cross, A.J., L ongden, A., Riley, G.J.: Increased dopamine-receptor sensitivity in schizophrenia. Lancet ii, 223–225 (1978).
Peroutka, S.J., Lebowitz, R. M., Snyder, S. H.: Two distinct serotonin receptors with different physiological functions. Science 212, 827–829 (1981).
Reynolds, G. P., Riederer, P., Jellinger, K., Gabriel, E.: Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology 20, 1319–1320 (1981).
Reynolds, G. P., Cowey, L., Rossor, M., Iversen, L.L.: Thioridazine is not specific for limbic dopamine receptors. Lancet ii, 499–500 (1982).
Whitaker, P. M., Crow, T.J., Ferrier, I. N.: Tritiated LSD binding in frontal cortex in schizophrenia. Arch. Gen. Psychiatry 38, 278–280 (1981).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Wien
About this paper
Cite this paper
Reynolds, G.P., Rossor, M.N., Iversen, L.L. (1983). Preliminary Studies of Human Cortical 5-HT2 Receptors and Their Involvement in Schizophrenia and Neuroleptic Drug Action. In: Goldstein, M., Jellinger, K., Riederer, P. (eds) Basic Aspects of Receptor Biochemistry. Journal of Neural Transmission, vol 18. Springer, Vienna. https://doi.org/10.1007/978-3-7091-4408-4_26
Download citation
DOI: https://doi.org/10.1007/978-3-7091-4408-4_26
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-4410-7
Online ISBN: 978-3-7091-4408-4
eBook Packages: Springer Book Archive